Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids

Biologicals

Volumn 43, Issue 5, 2015, Pages 318-332

  Hamilton, Gregory S ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

ADCs; Antibody drug conjugate; Immunoconjugate; Oncology; Targeted therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AURISTATIN; CALICHEAMICIN; CARBOXYLIC ACID; DAUNORUBICIN; DISULFIDE; DUOCARMICIN; HYDRAZONE DERIVATIVE; MAYTANSINOID; N SUCCINIMIDYL 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE; PACLITAXEL; PEPTIDE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; BIOLOGICAL PRODUCT;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONJUGATE; DRUG ANALYSIS; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; NEOPLASMS;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84941317860     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2015.05.006     Document Type: Review

References (97)

1. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23. 1157-1157.
2. Vogel C.L., et al. First line herceptin monotherapy in metastatic breast cancer. Oncology 2001, 2(61 Suppl.):37-42.
3. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001, 2(61 Suppl.):14-21.
4. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010, 9:767-774.
5. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
6. Reichert J.M., Rosensweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005, 23:1073-1078.
7. Reichert J.M. Marketed therapeutic antibodies compendium. MAbs 2012, 4:413-415.
8. Chari R.V. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008, 41:98-107.
9. Zolot R.S., Basu S., Million R.P. Antibody-drug conjugates. Nat Rev Drug Discov 2013, 12:259-260.
10. Prabhu S., Boswell C.A., Leipold D., Khawli L.A., Li D., Lu D., et al. Antibody delivery of drugs and radionuclides; factors influencing clinical pharmacology. Ther Deliv 2011, 2:769-791.
11. Chen F., Hong H., Zhang Y., Valdovinos H.F., Shi S., Kwon G.S., et al. In vivo tumor targeting and image-guided drug delivery with antibody conjugated, radiolabeled mesporous silica nanoparticles. ACS Nano 2013, 7:9027-9039.
12. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480.
13. O'Mahony D., Bishop M.R. Monoclonal antibody therapy. Front Biosci 2006, 11:1620-1635.
14. Hughes B. Antibody-drug conjugates for cancer: poised to deliver?. Nat Rev Drug Discov 2010, 9:665-667.
15. Reichert J.M., Rosenweig C.J., Faden L.B., Dewitz M.C. Monoclonal antibody successes in the clinic. Nat Biotech 2005, 23:1073-1078.
16. Nelson A.L., Dhimolea E., Reichert J.M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Disc 2010, 9:767-774.
17. Morrison S.L., et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U. S. A 1984, 81:6851-6855.
18. Boulianne G.L., et al. Production of functional chimaeric mouse/human antibody. Nature 1984, 312:643-646.
19. Cole S.P., Campling B.G., Atlaw T., Kozbor D., Roder J.C. Human monoclonal antibodies. Mol Cell Biochem 1984, 62:109-120.
20. Carson D.A., et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv Immunol 1986, 38:275-311.
21. Webb S. Pharma interest surges in antibody drug conjugates. Nat Biotech 2011, 29:297-298.
22. http://www.fiercebiotech.com/story/adimab-mersana-strike-deal-make-antibody-drug-combos-pharma/2012-08-01.
23. Moffatt F. Antibody-drug conjugates - challenges of combining small and large molecules. Solvias Prospects Jan. 2010, 13-22.
24. Jaracz S., Chen J., Kuznetsova L.V., Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005, 13:5043-5054.
25. Ducry L., Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010, 21:5-13.
26. Erickson H.K., Park P.U., Widdison W.C., et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006, 66:4426-4433.
27. Sanderson R.J., Hering M.A., James S.F., et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005, 11:843-852.
28. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988, 48:7022-7032.
29. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104.
30. Dreher R.D., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.
31. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
32. Alley S.C., Okeley N.M., Senter P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010, 14:529-537.
33. Beck A., et al. The next generation of antibody-drug conjugates comes of age. Discov Med 2010, 10:329-359.
34. Trail P.A. Antibody drug conjugates as cancer therapeutics. Antibodies 2013, 2:113-119.
35. Ritter A. Antibody-drug conjugates: looking ahead to an emerging class of biotherapeutic. Pharm Tech 2012, 36:42-47.
36. Junttila T.T., Li G., Parson K., Phillips G.L., Sliwkowski M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib-insensitive breast cancer. Breast Cancer Res Treat 2011, 128:347-356.
37. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
38. Gerber H.P., Senter P.D., Grewal I.S. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 2009, 1:247-253.
39. Staerz U.D., Bevan M.J. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci 1986, 83:1453-1457.
40. Xiang J., Pan Z., Attah-Poku S., Babiuk L., Zhang Y., Liu E. Production of hybrid bispecific antibody recognizing human colorectal carcinoma and CD3 antigen. Mol Biother 1992, 4:15-23.
41. Goldmacher V.S., Kovtun Ther Y.V. Deliv. 2011, 2:397-416. 29.
42. http://www.biooncology.com/research-education/adc/current-research.
43. Jeffrey S.C., Burke P.J., Lyon R.P., Meyer D.W., Sussman D., Anderson M., et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013, 24:1256-1263.
44. Jawad M., Seedhouse C., Mony U., Grundy M., Russell N.H., Pallis M. Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 2010, 24:74-80.
45. Aird R.E., Thomson M., Macpherson J.S., Thurston D.E., Jodrell D.I., Guichard S.M. ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136. Pharmacogenomics 2008, 8:289-296.
46. Guichard S.M., Macpherson J.S., Thurston D.E., Jodrell D.I. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136. Eur J Cancer 2005, 41:1811-1818.
47. Yu D.S., Chang S.Y., Ma C.P. The expression of MDR-1-related GP-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 1998, 82:544-547.
48. Walsh N., Larkin A., Kennedy S., Connolly L., Ballot J., Ooi W., et al. Expression of multidrug-resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol 2009, 9:6.
49. Moon S.-J., Govindan S.V., Cardillo T.M., D'Souza C.A., Hansen H.J., Goldenberg D.M. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008, 51:6916-6926.
50. Govindan S.V., Cardillo T.M., Moon S.-J., Hansen H.J., Goldenberg D.M. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009, 15:6052-6061.
51. Cardillo T.M., Govindan S.V., Sharkey R.M., Trisal P., Goldenberg D.M. Humanized anti-trp-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011, 17:3157-3169.
52. Sharkey R.M., Govindan S.V., Cardillo T.M., Goldenberg D.M. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 2012, 11:224-234.
53. Govindan S.J., Goldenberg D.M. Sci World J 2010, 10:2070-2089.
54. Barar J., Omidi Y. Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts 2014, 4:3-14.
55. Polson A.G., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009, 69:2358-2364.
56. Lewis Phillips G.D., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290.
57. Erickson H.K., et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010, 21:84-92.
58. Advani A., et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamacin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010, 28:2085-2093.
59. Doronina S.O., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
60. Dubowchik, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 2002, 13:855-869.
61. Doronina S.O., Bovee T.D., Meyer D.W., Miyamoto J.B., Anderson M.E., Morris-Tilden C.A., et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 2008, 19:1960-1963.
62. Burke P.J., Toki B.E., Meyer D.W., Miyamoto J.B., Kissler K.M., Anderson M., et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorg Med Chem Lett 2009, 19:2650-2653.
63. Jeffrey S.C., Nguyen M.T., Andreyka J.B., Meyer D.L., Doronina S.O., Senter P.D. Dipeptide-based highly potent doxorubicin antibody conjugates. Bioorg Med Chem Lett 2006, 16:358-362.
64. Antibody-drug conjugates and immunotoxins: from preclinical development to therapeutic applications 2013, Humana Press. G.L. Phillips (Ed.).
65. Erickson H. Antibody-maytansinoid conjugates for Cancer therapy. Presentation at AAPS national biotechnology conference, San Francisco May 19, 2010.
66. Castaneda L., Maruani A., Schumacher F.F., Miranda E., Chudsama V., Chester K.A., et al. Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation. Chem Commun 2013, 49:8187-8189.
67. Papisov M.I., Hiller A., Yurkovetskiy A., Yin M., Barzana M., Hillier S., et al. Semisynthetic hydrophilic polyals. Biomacromolecules 2005, 5:2659-2670.
68. US 8,685,383; US 8,808,679; US 8,815,226; and US 8,821,850.
69. http://www.concortis.com/technology.
70. Kamath A.V., Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Phar Res 2014, 10.1007/s11095-014-1584-z.
71. Wright A., Sato Y., Okada T., Chang K., Endo T., Morrison S. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 2000, 10:1347.
72. Erickson H.K., Lambert J.M. ADME of antibody-maytansinoid conjugates. AAPS J 2012, 14:799-805.
73. Boswell C.A., Mundo E.E., Zhang C., Bumbaca D., Valle N.R., Kozak K.R., et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011, 22:1994-2004.
74. Erickson H.K., Lewis-Phillips G.D., Leipold D.D., Provenzano C.A., Mai E., Johnson H.A., et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 2012, 11:1133-1142.
75. Miksinski S.P., Shapiro M. Regulatory considerations for antibody-drug conjugates. AAPS Meet October 18, 2012, Accessed atwww.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM341177.pdf.
76. Shapiro M.A., Chen X.-H. Regulatory considerations when developing assays for the characterization and quality control of antibody-drug conjugates. Amer Lab Aug. 27, 2012, accessed at http://www.americanlaboratory.com/913-Technical-Articles/119843-Regulatory-Considerations-When-Developing-Assays-for-the-Characterization-and-Quality-Control-of-Antibody-Drug-Conjugates/.
77. Wakankar A., Chen Y., Gokarn Y., Jacobson F.S. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011, 3:161-172.
78. Ouyang J. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Methods Mol Biol 2013, 10425:275-283.
79. Quiles S., Raisch K.P., Sanford L.L., Bonner J.A., Safvay A. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem 2010, 53:586-594.
80. Safvay A., Bonner J.A., Waksal H.W., Buchsbaum D.J., Gillespie G.Y., Khazaeli M.B., et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 2003, 14:302-310.
81. Wang L., Amphlett G., Blattler W.A., Lambert J.M., Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005, 14:2436-2446.
82. rd annual world ADC meeting October 25, 2012, Accessed at. http://adc-summit.com/uploads/files/1972/Michelle_Dougherty.pdf.
83. Hart B. Special considerations for the antobody-drug conjugate IND. 3rd annual world ADC meeting October 25, 2012, Accessed at http://adc-summit.com/uploads/files/1972/Bruce:Hart.pdf.
84. Pharmaceutical Quality for the 21st Century: A Risk-Based Approach http://www.fda.gov/oc/cgmp/report0507.html.
85. ICH Quality Guidelines: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
86. B. Antibody drug conjugates (ADCs): Considerations for specifications and impurities. Accessed at http://www.aaps.org/uploadedfiles/content/sections_and_groups/focus_groups/cmcmtgtopicintros2011.pdf.
87. Harris J., Jacobson F., Jochheim C., Amphlett G., Francissen K., McLeod L. Uniting small molecule and biologic drug perspectives. BioProces Intl 2011, 9:12-22.
88. Hughes B. Gearing up for follow-on biologics. Nat Rev Drug Discov 2009, 8:181.
89. Petak I., Schwab R., Orfi L., Kopper L., Keri G. Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 2010, 9:523-535.
90. Beck A. The next generation of antibody-drug conjugates come alive. Discov Med 2010, 13:297.
91. Naumovski L., Junutula J.R. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb amd monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 2010, 12:248-257.
92. Lu D., Sahasranaman S., Zhang Y., Girish S. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development. Bioanalysis 2013, 9:1115-1130.
93. Salvi V., Karnad D.R., Panicker D.K., Kothari S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010, 159:34-48.
94. Gupta M., Wang B., Carrothers T.J., Joshi A., LoRusso P.M., Chu W., et al. Exposure-response analysis in patients with HER2-positive (HER2+) metastatic breast cancer (MBC) to assess the effect of T-DM1 on QTc prolongation. Presentation at ASPCT conference in Dallas, TX March 4, 2011, Accessed at. http://www.go-acop.org/sites/default/files/webform/Manish_Gupta.doc.
95. Chao G., Lau W.L., Hackel B.J., Sazinsky S.L., Lippow S.M., Wittrup K.D. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 2006, 1:755-768.
96. Estep P., Reid F., Nauman C., Liu Y., Sun T., Sun J., et al. High throughput solution-based measurement of antibody-antigen affinity and epitope binning. MAbs 2013, 5:270-278.
97. Shaun M., Lippow K., Wittrup D., Tidor B. Computational design of antibody affinity improvement beyond in vivo maturation. Nat Biotechnol 2007, 25:1171-1176.